Oral
Herpes zoster (shingles)
Adult: Immunocompetent patients: 1,000 mg tid for 7 days. Immunocompromised patients: 1,000 mg tid for at least 7 days and for 2 days after crusting of lesions.
Renal impairment: Patient on haemodialysis: Lowest recommended dose after the dialysis session.
CrCl (ml/min) | Dosage Recommendation |
30-49 | Immunocompetent and immunocompromised patients: 1,000 mg bid. |
10-29 | Immunocompetent and immunocompromised patients: 1,000 mg once daily. |
<10 | Immunocompetent and immunocompromised patients: 500 mg once daily. |
Oral
Herpes zoster ophthalmicus
Adult: Immunocompetent patients: 1,000 mg tid for 7 days. Immunocompromised patients: 1,000 mg tid for at least 7 days and for 2 days after crusting of lesions.
Renal impairment: Patient on haemodialysis: Lowest recommended dose after the dialysis session.
CrCl (ml/min) | Dosage Recommendation |
30-49 | Immunocompetent and immunocompromised patients: 1,000 mg bid. |
10-29 | Immunocompetent and immunocompromised patients: 1,000 mg once daily. |
<10 | Immunocompetent and immunocompromised patients: 500 mg once daily. |
Oral
Herpes simplex infections of skin and mucous membranes
Adult: Immunocompetent patients: 500 mg bid for 3-5 days for recurrent episodes or for up to 10 days for initial episodes. Immunocompromised patients: 1,000 mg bid for at least 5 days for recurrent episodes or for up to 10 days for initial episodes. Treatment duration is based on severity of clinical condition and immunological status.
Child: ≥12 years Same as adult dose.
Renal impairment: Patient on haemodialysis: Lowest recommended dose after the dialysis session.
CrCl (ml/min) | Dosage Recommendation |
≥30 | Immunocompetent patients: 500 mg bid. Immunocompromised patients: 1,000 mg bid. |
<30 | Immunocompetent patients: 500 mg once daily. Immunocompromised patients: 1,000 mg once daily. |
Oral
Genital herpes
Adult: Immunocompetent patients: 500 mg bid for 3-5 days for recurrent episodes or for up to 10 days for initial episodes. Immunocompromised patients: 1,000 mg bid for at least 5 days for recurrent episodes or for up to 10 days for initial episodes. Treatment duration is based on severity of clinical condition and immunological status.
Child: ≥12 years Same as adult dose.
Renal impairment: Patient on haemodialysis: Lowest recommended dose after the dialysis session.
CrCl (ml/min) | Dosage Recommendation |
≥30 | Immunocompetent patients: 500 mg bid. Immunocompromised patients: 1,000 mg bid. |
<30 | Immunocompetent patients: 500 mg once daily. Immunocompromised patients: 1,000 mg once daily. |
Oral
Prophylaxis of cytomegaloviral infections in immunocompromised patients
Adult: Patient following solid organ transplantation: 2,000 mg 4 times daily, usually for 90 days according to patient response.
Child: ≥12 years Same as adult dose.
Renal impairment: Patient on haemodialysis: 1,500 mg once daily.
CrCl (ml/min) | Dosage Recommendation |
50-74 | 1,500 mg 4 times daily. |
25-49 | 1,500 mg tid. |
10-24 | 1,500 mg bid. |
<10 | 1,500 mg once daily. |
Oral
Herpes labialis
Adult: 2,000 mg 12 hourly for 1 day.
Child: ≥12 years Same as adult dose.
Renal impairment: Patient on haemodialysis: Lowest recommended dose after the dialysis session.
CrCl (ml/min) | Dosage Recommendation |
30-49 | 1,000 mg 12 hourly for 1 day. |
10-29 | 500 mg 12 hourly for 1 day. |
<10 | 500 mg as a single dose. |
Oral
Suppression of recurrent herpes simplex
Adult: Immunocompetent patients: 500 mg once daily. Patient with ≥10 relapses a year: 250 mg bid. Immunocompromised patients: 500 mg bid. Re-evaluate treatment after 6-12 months of therapy.
Child: ≥12 years Same as adult dose.
Renal impairment:
CrCl (ml/min) | Dosage Recommendation |
≥30 | Immunocompetent patients: 500 mg once daily; Patient with ≥10 relapses a year: 250 mg bid; Immunocompromised patients: 500 mg bid. |
<30 | Immunocompetent patients: 250 mg once daily. Immunocompromised patients: 500 mg once daily. |